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The microtubule (MT)-associated protein tau is important in neu-
ronal development and in Alzheimer’s and other neurodegenera-
tive diseases. Genetic analyses have established a cause-and-effect
relationship between tau dysfunctionmisregulation and neuronal
cell death and dementia in frontotemporal dementia and parkin-
sonism associated with chromosome 17; several mutations causing
this dementia lead to increased ratios of four-repeat (4R) to
three-repeat (3R) wild-type tau, and an attractive hypothesis is that
the abnormally high ratio of 4R to 3R tau might lead to neuronal
cell death by altering normal tau functions in adult neurons. Thus,
we tested whether 3R and 4R tau might differentially modulate the
dynamic instability of MTs in vitro using video microscopy. Al-
though both isoforms promoted MT polymerization and decreased
the tubulin critical subunit concentration to approximately similar
extents, 4R tau stabilized MTs significantly more strongly that 3R
tau. For example, 4R tau suppressed the shortening rate, whereas
3R tau had little or no detectable effect. Similarly, 3R tau had no
effect on the length shortened during a shortening event, whereas
4R tau strongly reduced this parameter. Further, when MTs were
diluted into buffer containing 4R tau, the MTs were stabilized and
shortened slowly. In contrast, when diluted into 3R tau, the MTs
were unstable and shortened rapidly. Thus, 4R tau stabilizes MTs
differently and significantly more strongly than 3R tau. We suggest
a ‘‘dosage effect’’ or haploinsufficiency model in which both tau
alleles must be active and properly regulated to produce appro-
priate amounts of each tau isoform to maintain MT dynamics
within a tolerable window of activity.
Many neurodegenerative diseases exhibit abnormal patho-logical fibers composed primarily of the microtubule
(MT)-associated protein, tau (for a recent review, see ref. 1).
These disorders, termed ‘‘tauopathies,’’ include Alzheimer’s
disease, frontotemporal dementia and parkinsonism associated
with chromosome 17 (FTDP-17), Pick’s disease, and progressive
supranuclear palsy. In 1998, several groups reported a direct
genetic linkage between mutations in the tau gene and FTDP-17
(2–5). Although some tau mutations are structural and others
are regulatory, all exhibit dominant phenotypes. Thus, both
dysfunction and misregulation of tau are causally related to
neuronal cell death, neurodegenerative disease, and dementia.
Tau is normally present predominantly in the cell bodies and
axons of neuronal cells and is necessary for the establishment of
neuronal cell polarity and axon outgrowth, axonal transport, and
maintenance of axonal morphology (6–10). Tau is also expressed
in glial cells (11). Mechanistically, tau stimulates MT polymer-
ization, stabilizes MTs, and suppresses MT dynamics (12–15).
Because MT dynamics must be tightly regulated for cells to
function and remain viable (e.g., ref. 16), it follows that the
action of tau must also be finely regulated.
Although there is only a single tau gene, alternative splicing of
tau mRNA produces six different isoforms in the CNS (17). The
isoforms fall into two groups (17, 18), one of which contains four
18-aa imperfect repeats near the C termini and the other, three
such repeats (Fig. 1). In both cases, the repeats are separated by
13- to 14-aa-long interrepeats. Previous work has shown that
four-repeat (4R) tau binds to MTs 3-fold more strongly than
three-repeat (3R) tau (19–21) and also assembles MTs more
effectively than 3R tau (22, 23).
The biological significance of tau RNA alternative splicing is
highlighted by two observations. First, tau isoform expression is
tightly regulated during development: whereas only the shortest
3R isoform is expressed in fetal neurons, all six tau isoforms are
expressed in adult human brain, with 3R and 4R tau being
expressed at approximately equal levels (5, 17, 18, 24–26).
Transition from the simple fetal to the complex adult expression
pattern coincides more or less temporally with the arrival of
growth cones at their targets, leading to the model that the
developmental transition of tau isoform expression reflects
different functional requirements for MTs in fetal vs. adult
neurons. The second observation highlighting the importance of
tau RNA splicing is that many FTDP-17 tau mutations are
regulatory mutations that alter the pattern of tau RNA splicing
without altering the primary sequence of the encoded tau
protein (2–4, 27). These mutations result in an increase in the
expression ratio of 4R to 3R tau in adult neurons, an alteration
sufficient to cause neuronal cell death and dementia. Thus, there
must be fundamentally important functional differences be-
tween 3R and 4R tau.
Although the genetic linkage between tau mutations and
FTDP-17 establishes a clear cause-and-effect relationship be-
tween tau dysfunctionmisregulation and neuronal cell death
and dementia, the underlying molecular mechanism leading to
dementia and neuronal cell death is not understood. In line with
the growing number of dominantly inherited degenerative dis-
eases involving abnormal protein folding (28), several investi-
gators have suggested a ‘‘gain-of-a-toxic-function’’ mechanism in
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Fig. 1. Schematic of 4R and 3R tau. Boxes above each line correspond to the
18-aa imperfect repeats. Dark boxes below each line correspond to regions
encoded by alternatively spliced exons. The inclusion or excision of sequences
encoded by the exon in the repeat region leads to the synthesis of 4R or 3R tau,
respectively. Arrows above the line mark the positions of amino acid substi-
tutions that lead to FTDP-17.
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which the mutations confer on tau an increased probability of
forming abnormal cytotoxic neurofibrillary tangles (5, 29). Al-
though this is a plausible model for FTDP-17 mutations that alter
the tau amino acid sequence, it is less obvious what toxic function
might be acquired by the tau RNA splicing mutations in which
only the ratio of otherwise wild-type proteins is affected.
To obtain a more mechanistic understanding of normal and
pathological tau action, we have analyzed the abilities of 3R and
4R tau to regulate the growing and shortening dynamics of
individual MTs in vitro using video microscopy. We find that the
abilities of 3R and 4R tau to suppress the rate and extent of MT
shortening and to stabilize MTs are different. On the basis of
these data, we propose an alternative to the gain-of-a-toxic-
function model of tau action. We suggest a ‘‘dosage effect’’ or
haploinsufficiency model in which both tau alleles must be active
and properly regulated to produce appropriate amounts of each
tau isoform to maintain MT dynamics within a tolerable window
of activity. In this model, migration outside the tolerable window
of dynamic activity leads to cell death. The model provides
insights into tau action during neurodegeneration resulting from
either tau dysfunction or misregulation, as well as during the
normal development and maintenance of neuronal function.
Materials and Methods
Purification of 3R and 4R Tau Isoforms and of Tubulin. Recombinant
full-length adult rat 4R and 3R tau were synthesized in Esche-
richia coli by using the pET vector expression system (Novagen)
(15). The tau concentration was determined by subjecting an
aliquot of a large tau sample to acid hydrolysis followed by MS
determination of the mass of each amino acid, by using known
amino acid standards for comparison. This assay revealed a
major discrepancy with the commonly used colorimetric or light
spectroscopic methods. Specifically, the MS assay revealed that
previously used colorimetric assays (and the extinction coeffi-
cient determined based on those assays) overestimated the
concentration of tau by 2.7-fold. Thus, a 1 mgml solution of
highly purified tau has an absorbance at 278 nm of 0.78 rather
than 0.29, as determined (30). Purified tau was stored at –70°C.
Bovine brain MT protein (70% tubulin and 30% MT-
associated proteins) was prepared by three cycles of assembly
and disassembly (31). Tubulin was purified from the MT protein
by elution through a Whatman P-11 phosphocellulose column
(32) and equilibrated in 50 mM Pipes1 mM MgSO41 mM
EGTA0.1 mM GTP. Purified tubulin (99% pure) was drop
frozen in liquid nitrogen and stored at –70°C.
Analysis of Dynamic Instability of Individual MTs by Video Microscopy.
Purified tubulin (10 or 12 M) was polymerized at the ends of
sea urchin (Strongylocentrotus purpuratus) axonemal seeds at
37°C in the presence or absence of the desired tau isoform in 87
mM Pipes36 mM Mes1.4 mM MgCl21 mM EDTA, pH 6.8
(PMME buffer). The dynamic instability behavior at the plus
ends of individual MTs was recorded at 37°C. The ends were
designated as plus or minus on the basis of the growth rate, the
number of MTs that grew at opposite ends of the seeds, and the
relative lengths of the MTs (15, 33). Dynamic instability was
analyzed both during the early elongation phase of polymeriza-
tion (at 10 M tubulin) and when the MT suspension was
approaching but not yet at steady state (12 M tubulin). For
analysis of dynamics at near steady state, usually 30 l of tubulin
solution was assembled onto the ends of the seeds for 30 min at
37°C. For analysis, 3 l of the suspension was applied to a
coverslip and prepared for video microscopy as described (15,
32). For analysis of dynamics during initial polymerization, 3 l
of a 10 M tubulin solution was mixed with axonemal seeds at
37°C and placed on a coverslip. The dynamics of individual MTs
were analyzed between 2 min and 7 or 8 min and not longer
than 10 min after initiation of polymerization. Data points were
collected at 3- to 5-s intervals. MT length changes with time were
determined as described (15). We considered a MT to be in a
growing phase if it increased in length by0.2 m at a rate0.3
mmin. MTs showing length changes 0.2 m over the dura-
tion of six data points were considered to be in an attenuated
state. Twenty to 30 MTs were analyzed for each experimental
condition.
Results
Effects of 3R and 4R Tau on the Tubulin Critical Subunit Concentration.
Before examining the effects of 3R and 4R tau on individual
dynamic instability parameters, we first compared their respec-
tive abilities to reduce the critical subunit concentration for MT
assembly using a sedimentation assay. Three- or 4R tau was
incubated with different concentrations of tubulin, and the MTs
were allowed to assemble for 30 min at 37°C. The MTs were then
separated from unassembled tubulin by sedimentation and the
protein content of the pellets determined. The critical concen-
tration for tubulin in the absence of added tau was10M (data
not shown). At the lower concentration of tau analyzed (0.09
M, Fig. 2A), both 4R and 3R tau strongly reduced the critical
concentration, with 4R tau doing so slightly more strongly than
3R tau (to 3.3 and 2.5 M tubulin for 3R and 4R tau, respec-
tively). At 0.74 M tau (Fig. 2B), 4R and 3R tau reduced the
critical concentration to the same extent, to 1.25 M tubulin. We
also compared the relative abilities of 3R and 4R tau to promote
MT polymerization. Whereas half-maximal MT assembly was
achieved by 4R tau at 0.11–0.15 M, half-maximal MT assembly
was achieved by 3R tau at 0.19–0.22 M (data not shown). Thus,
consistent with earlier work (e.g., refs. 22 and 23), both 3R and
Fig. 2. The effects of 3R (circles) and 4R tau (squares) on the tubulin critical
subunit concentration. MTs were assembled at 37°C in the presence of 0.09M
tau isoforms (A) or 0.74 M isoforms (B). After 30 min, the MTs were sedi-
mented at 150,000g in a Beckman TL100 centrifuge (Beckman Coulter). The
quantity of polymer was determined after dissolving the MT pellets in 100 l
of 100 mM Pipes1 mM MgS041 mM EGTA, pH 6.8, at 0°C for 1 h.
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4R tau promote MT assembly, with 4R tau doing so somewhat
more effectively than 3R tau.
3R and 4R Tau Differentially Modulate MT Dynamics both Near Steady
State and During the Initial Phase of Polymerization. The effects of
subsaturating concentrations of 3R and 4R tau on the in vitro
dynamic instability parameters at the plus ends of individual
MTs were first analyzed near steady state (Fig. 3). Similar to
work carried out at steady state (15), 0.74 M 4R tau (tau
tubulin molar ratio of 1:16) strongly suppressed the dynamic
instability behavior of the MTs. Importantly, 4R tau strongly
reduced the rate and extent of shortening compared with control
MTs (Fig. 3, compare A and B), whereas 3R tau did not appear
to affect these parameters (Fig. 3 A and C).
The differential effects of 3R and 4R tau on several of the
dynamic instability parameters near steady state are shown
quantitatively in Table 1. 3R and 4R tau promoted the rate of
MT growth similarly. Specifically, 0.74 M 4R tau increased the
growth rate 46% from 0.96 m per min to 1.4 m per min,
whereas 0.74 M 3R tau increased the growth rate by 42% to
1.36 m per min. In addition, both 3R and 4R tau reduced the
overall dynamicity of the MTs to approximately similar extents.
In marked contrast, 3R and 4R tau affected the rate of short-
ening very differently. 4R tau (0.74 M) reduced the shortening
rate by 54% from 36.2 to 16.7 m per min, whereas 0.74 M 3R
tau reduced the shortening rate by only 19%, to 28.8 m per min.
Similarly, the length the average MT shortened during a short-
ening event was unaffected by 0.74 M 3R tau, whereas it was
reduced 43% by 4R tau.
The differential effects of 3R and 4R tau on the rate and
extent of shortening were even more pronounced when their
effects on dynamics were analyzed during the early phase of
polymerization (Table 2). The effects of 3R tau were analyzed
at tautubulin ratios between 1:110 (0.09 M 3R tau) and 1:27
(0.37M 3R tau) and of 4R tau at tautubulin ratios of 1:54 (0.19
M 4R tau) and 1:27 (0.37 M 4R tau). Similar to what occurred
near steady state, 3R and 4R tau promoted the rate of MT
growth to similar extents. Both 3R and 4R tau also increased the
length grown during a growth event to the same extent. In
contrast, 3R and 4R tau exerted very different effects on the rate
and extent of shortening. Specifically, 0.19 M 4R tau sup-
pressed the shortening rate by 37% from 26.8 to 17 mmin, and
0.37 M 4R tau suppressed this rate by 53%. In contrast, 3R tau
had no detectable effect on the shortening rate at any concen-
tration. Similarly, 0.37 M 3R tau had no apparent effect on the
length shortened during shortening events, whereas 0.37 M 4R
tau strongly reduced this parameter (Table 2).
Differential Ability of 3R and 4R Tau to Stabilize MTs. To indepen-
dently confirm the differential actions of 3R and 4R tau on MT
stability, we assembled MTs to steady state at 12 M tubulin in
the absence of tau and then diluted the MT suspensions 4-fold,
either into a solution of 0.74 M 3R tau or 0.74 M 4R tau or
into buffer containing no tau. When no tau was present, the MTs
disassembled immediately, because the 4-fold dilution drops the
tubulin concentration well below the critical concentration for
assembly (data not shown). When the MTs were diluted into 4R
tau, they were quite stable, and when they shortened, they did so
slowly (Fig. 4A). In contrast, when diluted into 3R tau, the MTs
were relatively unstable and shortened rapidly (Fig. 4B). Thus,
3R tau exerted a significantly weaker ability to stabilize MTs
than 4R tau.
Fig. 3. Life history traces; the effects of 0.74 M 3R and 4R tau on the
dynamics of individual MTs at 37°C near steady state. The growing and
shortening dynamic of individual MTs was determined by video microscopy
(see Materials and Methods). (A) Control (no added tau). (B) 4R tau. (C) 3R tau.
Each trace represents a single MT.
Table 1. Effects of 3R and 4R tau on several dynamic instability parameters at microtubule
plus ends in vitro near steady state
Control
3R tau, m 4R tau, m
0.37 0.74 0.74
Rate, m/min
Growing 0.96  0.1 1.1  0.12 1.36  0.24 1.4  0.14
Shortening 36.2  3.0 29.5  3.1 28.8  5.9 16.7  3
Length excursion, m per event
Growing 1.8  0.24 2.0  0.22 1.9  0.2 1.4  0.14
Shortening 6  0.6 8.4  0.95 7.2  1.2 3.4  0.5
Dynamicity, m/min 2.45 2.38 1.26 2
Data are SEM except for transition frequencies, which are SD.
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Discussion
The most important finding described here is that, under con-
ditions in which 4R and 3R tau promote the rate and extent of
MT growth similarly, 4R tau strongly suppresses the rate and
extent of MT shortening, whereas 3R tau has minimal effect on
these parameters. These isoform-specific mechanistic differ-
ences are consistent with earlier competition (34) and structure–
function (21) studies suggesting that 4R and 3R tau interact with
MTs with at least some distinct molecular mechanisms. The data
indicate that 4R tau stabilizes MTs differently and substantially
more strongly than 3R tau. Ongoing work in our laboratories has
established that these same differences between the actions of
microinjected 4R and 3R tau on the growth and shortening
dynamics of MTs also occur in living cells (J. Bunker, M. A.
Jordan, L.W., and S.C.F., unpublished results). The increased
ability of 4R tau to stabilize neuronal MTs as compared with 3R
tau may play a role in neuronal cell death and dementia in
FTDP-17 individuals expressing altered 4R3R tau ratios.
There have been few detailed studies on the effects of tau on
MT dynamics. Initially, Drechsel et al. (13) found that 4R tau at
high concentrations close to those saturating the tau-binding
sites on the MT surface strongly promotes the rate and extent of
polymerization, decreases the transition frequency from the
growing to the shortening state, and inhibits the rate of depo-
lymerization. Trinczek et al. (14) examined the effects high
concentrations of 3R and 4R tau on various dynamic instability
parameters during the initial stages of MT polymerization and
observed similar but not identical effects. Especially relevant to
the work described here, 4R tau exerted a markedly stronger
ability to slow the tubulin dissociation rate at MT ends than 3R
tau.
In a previous report, we found that very low concentrations of
4R tau powerfully suppress MT dynamics (15). The ratios of 4R
tau to tubulin in the MTs used in that work, here corrected for
the tau concentration as determined by MS, varied between
1:473 at 0.028 M 4R tau (previously reported as 0.075 M tau)
and 1:27 at 0.44 M tau (previously reported as 1.2 M tau).
These extremely low ratios reduced the rate and extent of
shortening and, because the MT suspension was at steady state,
they also reduced the rate and extent of growth. 4R tau also
markedly increased the percentage of total time that the MTs
spent in an attenuated (paused) state, neither growing nor
shortening detectably.
Of considerable interest, the suppressing action of low tau
concentrations on MT dynamics resembles the action on dynam-
ics of the MT-stabilizing drug taxol. Like tau, taxol also binds
strongly to MTs, possibly to the same site at which tau binds (35),
and suppresses dynamics at very low ratios of taxol bound per
molecule of tubulin in the MTs (36). Such actions of low
microtubule-associated protein concentrations (MAPs) support
the idea that drugs such as taxol and other drugs that modulate
MT dynamics are mimicking the action of regulatory MAPs
(36, 37).
Mechanistic Implications for Tau-Mediated Neuronal Cell Death and
Disease: Gain of a Toxic Function or a Dosage Effect? Tau dysfunction
(e.g., accumulation of ‘‘neurofibrillary tangles’’) is correlated
with a number of neurodegenerative disorders (1), and the
recent identification of tau mutations linked to FTDP-17 (2–4)
demonstrates that errors in tau action or regulation lead to
neuronal cell death and dementia. There are two classes of
FTDP-17 mutations. One involves alteration of tau RNA splicing
that results in an increase in the ratio of wild-type 4R to 3R tau
Table 2. Effects of 3R and 4R tau on dynamic instability at plus ends of individual microtubules in vitro during
the early elongation phase of polymerization
Parameter
3R tau, M 4R tau, M
0 (control) 0.09 0.19 0.37 0.19 0.37
Rate, m/min
Growing 1.2  0.2 1.4  0.3 1.7  0.3 1.8  0.3 1.4  0.4 1.9  0.5
Shortening 26.8  6.1 26.4  8.0 31  16.8 26  9 17.0  6.2 12.5  5.5
Length excursion, m per event
Growing 5.3  3.7 6.2  3 7.1  3.5 8.5  5.7 7.6  4.5 8.5  3
Shortening 8.8  4 8.8  3.3 8.1  2.5 10  9 7.1  2.9 1.9  1
Percent time in phase
Growing 94 97.9 95 98 96.6 99
Shortening 6 2.1 5 2 3.4 1
Dynamicity, m/min 2.7 2.6 2.2 1.9 1.7 2
Data areSEM. The effects of 3R and 4R tau were analyzed on the dynamic instability parameters at MT plus ends during the growth
(elongation) phase of polymerization, between 2 and 10 min after initiation of polymerization.
Fig. 4. The effects of 3R and 4R tau on the stability of individual MTs after
dilution-induced disassembly. MTs were polymerized in PMME buffer at 37°C
(12 M tubulin) and diluted 4-fold into PMME buffer containing 0.74 M 4R
(A) or 3R tau (B). The diluted MT suspensions were analyzed between 2 and 10
min after dilution. Each trace represents a single MT.
Panda et al. PNAS  August 5, 2003  vol. 100  no. 16  9551
N
EU
RO
SC
IE
N
CE
(2–4, 27). The second are point mutations resulting in amino acid
substitutions. The majority of the point mutations map to the
repeat and interrepeat region of tau or lie immediately adjacent
to it (2–4), in sequences known to mediate or regulate tau’s MT
binding and assembly activities (Fig. 1; see also refs. 19–21, 34,
38, and 39). The initial in vitro analyses of point-mutated tau
proteins revealed relatively subtle reductions in MT-binding and
assembly activities (5, 40–42). Many point-mutated proteins also
increase tau fiber formation activity in vitro (29, 41, 43, 44). The
final important clue to tau action provided by the FTDP-17
mutations is that all of the mutations exhibit dominant rather
than recessive phenotypes.
A number of investigators have suggested that the molecular
mechanism underlying FTDP-17 tau-mediated neuronal cell
death might involve the gain of a toxic function, consistent with
the dominance of the phenotype. One idea is that the mutated
tau polypeptides may have acquired an increased capability to
form toxic fibers (5, 29). Although a plausible model to explain
the substitution mutations, it is less obvious what new activity
would account for cell death in the RNA splicing mutations,
because the tau proteins remain wild type. On the basis of the
data presented here, we propose an alternative model to explain
FTDP-17 mutant phenotypes based on dosage effects. We
suggest that the properly regulated activities of both tau alleles
are necessary to produce appropriate amounts of each isoform
to maintain MT dynamics within the narrow range required for
cell function and viability (Fig. 5). If MT dynamics in neurons
migrate outside this range, becoming too rapid or too sup-
pressed, cell functions dependent on the dynamics will be
impaired and, in time, cell death could occur.
This dosage model can readily account for both the RNA
splicing and amino acid substitution classes of FTDP-17 muta-
tions. With the RNA splicing mutations, increasing the ratio of
4R to 3R tau will lead to less MT shortening and increased MT
stabilization. With the mutations causing amino acid substitu-
tions, most of the mutated tau molecules possess defects in
MT-binding andor assembly activities (e.g., see refs. 5, 40, and
42), and cells expressing such mutated tau proteins are likely to
have overly dynamic MTs. Our model predicts that cell death
should occur in both classes of mutations, because the pattern of
MT dynamics would migrate outside the window of viability, one
way or the other.
Evidence for the need to maintain MT dynamics within a
narrow window has recently been obtained in mitotic cells.
Specifically, low concentrations of taxol powerfully suppress MT
dynamics in mitotic spindles of dividing cells, resulting in the
inability of the cells to progress normally from metaphase to
anaphase (45, 46). Low concentrations of taxol that suppress
spindle MT dynamics by only 15–25% are sufficient to impair
mitotic progression and induce apoptosis (for example, refs. 45
and 46). Moreover, in lung tumor A549 cells that are both
resistant to taxol and dependent on the presence of taxol for
viability, removal of taxol results in a significant increase in MT
dynamics (16). Importantly, on removal of taxol, the dependent
cells become blocked in mitosis and die, as do their wild-type
counterparts treated with normal taxol concentrations. Thus,
during mitosis, there appears to be a narrow window of tolerated
MT dynamics, and excessively rapid dynamics as well as sup-
pressed dynamics lead to mitotic inhibition and cell death (16).
A dosage effect model has additional important features.
First, it can accommodate the longstanding correlation between
tau hyperphosphorylation and neuronal cell death. Because
most tau phosphorylation events reduce tau’s binding affinity for
MTs, they are also likely to reduce the ability of tau to regulate
MT dynamics. Indeed, phosphorylation of tau by MAP2 kinase
(13), MARK, or cdk5 (14) reduces tau’s ability to influence MT
dynamics. If the reduction of dynamics-regulating activity is
sufficient to move the cell outside the dynamics window required
for viability, the model predicts cell death. A second feature of
the model is that abnormal tau fiber formation is relegated to a
downstream consequence of the primary cause of cell death,
which is abnormal tau effects on MT dynamics. In this regard,
Drosophila-overexpressing human tau exhibit many features of
Alzheimer’s disease, including early onset and progressive neu-
rodegeneration, but without abnormal tau fiber formation (47).
Thus, abnormal tau fiber formation is not an obligatory feature
of tau-induced neuronal cell death.
Finally, the dosage effect and gain-of-toxic-function models
are not mutually exclusive. In addition to the possibility that the
fibers may themselves be toxic under some circumstances, fiber
formation would be expected to contribute to deregulation of
MT dynamics by virtue of sequestering the pool of tau, which
should in turn lead to overly dynamic MTs and subsequent cell
death.
How Might Altered MT Dynamics Cause Cell Death? In nonneuronal
dividing cells, drugs that alter MT dynamics can lead to aberrant
cell movement, cell morphology, chromosome segregation, and
intracellular transport mechanisms (48). Although chromosome
segregation and major cell movements are not highly relevant for
postmitotic neurons, neurons should be very sensitive to per-
turbations affecting axonal transport or the maintenance of cell
morphology. Hence, if altered neuronal MT dynamics underlie
tau-mediated neuronal cell death in FTDP-17 disease, the actual
cause of cell death might be the inability to properly transport
cargo along the axon andor to maintain the elongated cell
morphology necessary to acquire and transport target-derived
trophic factors. Indeed, overexpression of tau in cultured neu-
ronal cells leads to aberrant axonal transport (10). Further,
compromising axonal transport via overexpression of dynactin in
mice causes late-onset death in motor neurons (49).
Implications for Normal Neuronal Development and Maintenance.
The transition from the simple fetal 3R tau expression pattern
to the more complex adult expression pattern (approximately
equal amounts of 3R and 4R tau) coincides approximately with
the arrival of growth cones at targets. This correlation has led to
the model that the developmental transition in tau isoform
expression confers on MTs the different functional capabilities
required in growing immature neurons vs. mature neurons.
However, the mechanistic rationale for the developmental reg-
Fig. 5. Dosage effect model for normal and pathogenic tau action. Cell
function and viability require properly regulated MT dynamics. Overly sup-
pressed dynamics, such as those that occur in the presence of taxol and, as we
propose, might occur in the FTDP-17 RNA splicing mutations, result in cell
death. Similarly, overly dynamic MTs, such as those that occur in taxol-resistant
and -dependent cells in the absence of taxol (16) and those that might occur
in the FTDP-17 missense mutations and in cells expressing hyperphosphory-
lated tau, also result in cell death.
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ulation of tau RNA splicing has remained elusive. On the basis
of the data presented here, the MTs in fetal neurons may be
significantly more dynamic that those in adult neurons. Inte-
grating this notion with the model schematized in Fig. 5 leads to
the conclusion that the window of acceptable dynamic behavior
shifts as development proceeds. This possibility is not without
precedent, because the level of MT dynamics can vary widely in
different cell types, within the same cell at different times in the
cell cycle, and even in different regions of the same cell (50, 51).
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